In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Existing investors put another $30mm into Calistoga

Executive Summary

Calistoga Pharmaceuticals (hematological cancers and inflammation) raised $30mm through its Series B round from existing backers Alta Partners, Amgen Ventures, Frazier Healthcare, and Three Arch Partners. To date, the company has raised over $56mm. The latest funds will go towards development of Calistoga's clinical-stage isoform-selective PI3K inhibitors.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies